CAR-T Therapy Targeting CD19 and CD20 Demonstrates High Responses in MCL

Results from a phase 1/2 trial investigating LV20.19 found that the CAR-T therapy was safe and effective in 11 patients with R/R MCL, with an ORR of 100% and no relapses seen after a median follow up of more than 1.5 years.3

“Our group has previously published data using a bispecific tandem anti-CD20 and anti-CD19 CAR T-cell construct as part of a phase 1 clinical trial where we identified a cell dose of 2.5×106 cells/kg to be the safe dose for future investigation…with durable responses 4 years out,” study presenter Nirav N. Shah, MD, an associate professor with the Medical College of Wisconsin in Milwaukee, Wisconsin, said.

Continue Reading

Eligible patients for this study must have failed 2 lines of therapy or relapsed after autologous or allogeneic HSCT. There was a dedicated arm of the study for patients with MCL in a single-stage phase 2 design, with the 3-month CR rate as the primary target endpoint.

There were 3 patients who were included in the safety run-in portion of the trial and 11 included in phase 2. The median age was 63 years and 93% of participants were male. Additionally, 93% of patients had received prior BTK inhibitor treatment and 79% had progressed after BTK inhibitor therapy.

At day 28, the ORR was 100%, with 71% being CRs and the investigators seeing evolution over time. At day 90, the ORR was 100% in the surviving 12 patients, 92% as CRs. The median PFS and OS were not met after nearly 2 years of follow up, with durable responses and only 1 relapse seen at 2 years postinfusion.

In terms of safety, 1 patient had nonrelapsed mortality due to gram-negative sepsis, although they were negative for minimal residual disease at the time. There were 2 grade 3 cases of immune effector cell-associated neurotoxicity syndrome. Of the 14 patients included, 13 experienced grade 1 to 2 cytokine release syndrome. No patients required admission to the intensive care unit during the first 28 days of the trial.

“In conclusion, bispecific LV20.19 CAR T-cells are safe and efficacious for multiply-relapsed and refractory mantle cell lymphoma with a day 90 CR rate of 92% among evaluable patients,” said Dr Shah. “These data hypothesize that the dual targeting of CD20, which is an important target in mantle cell lymphoma outside of CAR-T, may be additive to CD19 and improve CAR-T therapy outcomes for patients with relapsed or refractory mantle cell lymphoma.”

A multicenter phase 2 trial is presently under development to validate these findings.

Disclosures: The MAGNOLIA study was sponsored by BeiGene and the TRANSFORM trial was sponsored by Celgene, a Bristol-Myers Squibb Company. Please see the original references for a full list of authors’ disclosures.


  1. Opat S, Tedeschi A, Hu B, et al. Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the Magnolia (BGB-3111-214) trial. Presented at: 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. Abstract 132.
  2. Abramson JS, Solomon SR, Arnason J, et al. Primary analysis results from the randomized, phase 3 transform study of lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma. Presented at: 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. Abstract 44.
  3. Shah NN, Furqan F, Szabo A, et al. Results from a phase 1/2 study of tandem, bispecific anti-CD20/anti-CD19 (LV20.19) CAR T-cells for mantle cell lymphoma. Presented at: 2023 Tandem Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR. Abstract 40.

This article originally appeared on Hematology Advisor